Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 18/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 18/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 18/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 18/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 18/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 18/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457885 | 0.85 | USP30 (0.46) | USP30PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8095955 | 0.82 | NR2E1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3040146 | 0.80 | PSEN1 (0.41) | USP30PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3045214 | 0.80 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6127819 | 0.80 | PSEN1 (0.43) | USP30PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1616928 | 0.77 | NR2E1 (0.46) | USP30PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3055463 | 0.77 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3056041 | 0.75 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6124276 | 0.75 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3040182 | 0.74 | CYP1A2 (0.55) | CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242150-B2 | Triazole derivatives for treating alzheimer'S disease and related conditions | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242150-B2 | Triazole derivatives for treating alzheimer'S disease and related conditions | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242150-B2 | Triazole derivatives for treating alzheimer'S disease and related conditions | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | SCHERING CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | SCHERING CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | SCHERING CORPORATION | 2010-09-02 | — | — | US | disclosed |
| WO-2008156580-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | BACE1, PSEN1, PSEN2 | USP30 1741/4885PSEN1 2/4885PSEN2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.